Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc.verified

ACOR

Price:

$0.661

Market Cap:

$821.03K

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the deve...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2006-02-10

Stock Exchange

NASDAQ

Ticker

ACOR

The Enterprise Value as of December 2024 (TTM) for Acorda Therapeutics, Inc. (ACOR) is 187.38M

According to Acorda Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 187.38M. This represents a change of 3.67% compared to the average of 180.75M of the last 4 quarters.

Acorda Therapeutics, Inc. (ACOR) Historical Enterprise Value (quarterly & annually)

How has ACOR Enterprise Value performed in the past?

The mean historical Enterprise Value of Acorda Therapeutics, Inc. over the last ten years is 766.27M. The current 187.38M Enterprise Value has changed 2.35% with respect to the historical average. Over the past ten years (40 quarters), ACOR's Enterprise Value was at its highest in in the December 2015 quarter at 2.03B. The Enterprise Value was at its lowest in in the December 2022 quarter at 154.12M.

Quarterly (TTM)
Annual

Average

766.27M

Median

533.53M

Minimum

150.56M

Maximum

2.01B

Acorda Therapeutics, Inc. (ACOR) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Acorda Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 56.07%

Maximum Annual Enterprise Value = 2.01B

Minimum Annual Increase = -63.65%

Minimum Annual Enterprise Value = 150.56M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023179.28M19.08%
2022150.56M-11.80%
2021170.69M-23.13%
2020222.05M-21.94%
2019284.45M-63.65%
2018782.61M-22.81%
20171.01B-0.93%
20161.02B-49.07%
20152.01B10.03%
20141.83B56.07%

Acorda Therapeutics, Inc. (ACOR) Average Enterprise Value

How has ACOR Enterprise Value performed in the past?

The current Enterprise Value of Acorda Therapeutics, Inc. (ACOR) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

166.84M

5-year avg

201.41M

10-year avg

766.27M

Acorda Therapeutics, Inc. (ACOR) Enterprise Value vs. Peers

How is ACOR’s Enterprise Value compared to its peers?

Acorda Therapeutics, Inc.’s Enterprise Value is less than Taisho Pharmaceutical Holdings Co., Ltd. (466.10B), less than Shionogi & Co., Ltd. (1.58T), greater than Vivesto AB (145.86M), less than Pacira BioSciences, Inc. (1.29B), greater than Sunshine Biopharma, Inc. (-5451158.00), greater than Lucy Scientific Discovery Inc. (2.06M), greater than Biofrontera Inc. (5.83M), greater than Jupiter Wellness, Inc. (47.04M), greater than Shuttle Pharmaceuticals Holdings, Inc. (3.36M), less than Lifecore Biomedical, Inc. (410.86M), greater than Journey Medical Corporation (92.82M), greater than Akanda Corp. (-3403200.00), greater than China Pharma Holdings, Inc. (6.88M), greater than Universe Pharmaceuticals INC (-1027372.00), greater than Sonoma Pharmaceuticals, Inc. (-218241.00), greater than Petros Pharmaceuticals, Inc. (6.22M), greater than Evoke Pharma, Inc. (1.09M), greater than Cumberland Pharmaceuticals Inc. (38.21M), greater than Agile Therapeutics, Inc. (7.87M), greater than PainReform Ltd. (-89853.00),

Build a custom stock screener for Acorda Therapeutics, Inc. (ACOR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Acorda Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Acorda Therapeutics, Inc. (ACOR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Acorda Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Acorda Therapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Acorda Therapeutics, Inc. (ACOR)?

What is the 3-year average Enterprise Value for Acorda Therapeutics, Inc. (ACOR)?

What is the 5-year average Enterprise Value for Acorda Therapeutics, Inc. (ACOR)?

How does the current Enterprise Value for Acorda Therapeutics, Inc. (ACOR) compare to its historical average?